glp-1 and kidney function receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of failure. Adverse events are mostly gastrointestinal Glucagon-like peptide 1(GLP-1) receptor agonists

However, in keeping with our data on receptor pharmacology, increasing the dose to 30 nmol kg 1 , tenfold higher than maximal doses from our studies, shows that tirzepatide does have insulinotropic activity in Glp1r -/- mice or in the presence of a GLP-1R antagonist 5 , demonstrating that tirzepatide can engage the GIPR in mouse beta cells at sufficiently high concentrations

B-12 also plays a crucial role in the production of red blood cells, helping to prevent anemia

The Safety Profile and What We Do Not Know One of the concerns that comes up frequently with telomerase activation is cancer risk

Trials up to 68 weeks safe